Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)
Status:
Completed
Trial end date:
2021-01-27
Target enrollment:
Participant gender:
Summary
The main purpose of study is to assess the dose-response relationship of BMS-986165 (Dose A
or Dose B once daily [QD]) at Week 16 in the treatment of participants with active PsA.